Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer

Catherine Lhommé, Florence Joly, Joan L. Walker, Andrea A. Lissoni, Maria O. Nicoletto, Gregory M. Manikhas, Mark M O Baekelandt, Alan N. Gordon, Paula M. Fracasso, William L. Mietlowski, Gary J. Jones, Margaret H. Dugan

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences